ジアゾキシド誘発性肺高血圧症のリスク因子としての13トリソミー
Kazu Ishikawa1,2, Hiro Nakao1,2, Daisuke Shinjo3
1Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan.
Annals of pediatric cardiology
|February 23, 2026
まとめ
ジアゾキシドは乳児に肺高血圧症(PH)を引き起こす可能性があります。13トリソミーは、低用量および利尿薬の使用下でも、このリスクを大幅に増加させます。これは、影響を受けた新生児における注意の必要性を強調しています。
科学分野:
- 小児薬理学
- 心臓病学
- 遺伝学
背景:
- ジアゾキシドは、先天性高インスリン血症の重要な治療薬です。
- 肺高血圧症(PH)は、ジアゾキシドに関連する重篤な有害事象です。
- ジアゾキシド誘発性PHのベースラインリスクを理解することは非常に重要です。
研究 の 目的:
- ジアゾキシド投与後の肺高血圧症(PH)発症のベースラインリスクを決定すること。
- ジアゾキシドで治療された子供におけるPHのリスク因子を特定すること。
主な方法:
- 先天性高インスリン血症のためにジアゾキシドで治療された15歳未満の子供65人を対象とした後向きコホート研究。
- PHの発症と患者背景に焦点を当て、電子カルテからデータを抽出しました。
- PHリスクを評価するためにベイズ推定を適用しました。
主要な成果:
- 65人の子供のうち5%(3人)がPHを発症しました。
- 13トリソミーはPHの有意なリスク因子でした(100% vs 0%、P < 0.001)。
- 出生時の体重が低いこともPHの発症と関連していました(P = 0.049)。
結論:
- 13トリソミーは、ジアゾキシド使用によるPHのリスクを大幅に高めます。
- 予防的利尿薬および低用量ジアゾキシドは、13トリソミー患者のPHを予防しない可能性があります。
- 13トリソミーおよび低出生体重の乳児にジアゾキシドを処方する際には注意が必要です。
関連する概念動画
Pulmonary Hypertension: Classification and Pathogenesis
703
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
703
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
671
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
671
Pneumothorax-I
1.7K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
1.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
506
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
Pulmonary Embolism I: Introduction
942
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
942
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.9K


